SeaStar Medical to Sponsor the Critical Care Time Podcast Series Covering Vital Medical Issues for Healthcare Professionals Who Care for Critically Ill Patients
30 6월 2023 - 9:00PM
SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device
company developing proprietary solutions to reduce the consequences
of hyperinflammation on vital organs, announces its primary
sponsorship of the first season of the Critical Care Time podcast
series. These 24 weekly podcasts will delve into vital medical
issues facing healthcare professionals who care for critically ill
patients. The first podcast in the series, “Undifferentiated Shock:
I,” will broadcast during the week of July 3rd and will be
available here.
Critical Care Time Podcast
“We are excited to partner with Critical Care
Time as the primary sponsor of its inaugural season. These podcasts
will share insightful discussions of issues faced by physicians who
care for the critically ill, whether the patient is in an intensive
care unit, emergency department, operating room or ambulance,” said
Kevin Chung, MD, Chief Medical Officer of SeaStar Medical. “We are
impressed by the Critical Care Time team of leading physicians and
are confident this podcast series will be a valuable educational
resource for critical care practitioners in their fight to save
lives.
“Our sponsorship allows SeaStar Medical to
connect with the healthcare professionals we are working to support
with our novel, patented Selective Cytopheretic Device. The SCD is
our cell-directed extracorporeal therapy that has the potential to
save the lives of critically ill patients afflicted with
organ-damaging hyperinflammation,” he added.
“We are tremendously grateful for SeaStar
Medical’s support in helping us achieve our dream of establishing
this podcast,” said Cyrus Askin, MD, podcast co-creator. “We intend
to take deep dives into some complex critical care issues including
respectful discussions of messy or controversial topics not
typically covered by other podcasts. Importantly, our focus will be
on telling the human stories behind the clinical practice of
medicine. After a year of planning, we are excited to finally go
live.”
About the
Critical Care Time
PodcastCritical Care Time strives to support all
who care for the critically ill patient. Our podcasts will embrace
a multi-modality learning environment that combines high-quality
audio, video and infographics to enhance the educational
experience. The first season of Critical Care Time is expected to
include 24 podcasts of approximately 30 minutes each available
here. For more information visit www.criticalcaretime.com or visit
us on Twitter, Instagram or YouTube.
About SeaStar
MedicalSeaStar Medical is a medical technology
company that is redefining how extracorporeal therapies can reduce
the consequences of excessive inflammation on vital organs. SeaStar
Medical’s novel technologies rely on science and innovation to
provide life-saving solutions to critically ill patients. The
Company is developing and commercializing cell-directed
extracorporeal therapies that target the effector cells that drive
systemic inflammation, causing direct tissue damage and secreting a
range of pro-inflammatory cytokines that initiate and propagate
imbalanced immune responses. For more information visit
www.seastarmedical.com or visit us on LinkedIn or Twitter.
Forward-Looking StatementsThis
press release contains certain forward-looking statements within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1955. These forward-looking
statements include, without limitation, SeaStar Medical’s
expectations with respect to the timing of regulatory approval of
its products, the expected timing on enrollment, generation of
study results, submission of PMA and other corporate milestones,
the ability of SCD to treat patients with AKI, and the potential
benefits of SCD to treat other diseases. Words such as “believe,”
“project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions are intended to identify such
forward-looking statements. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to significant risks and uncertainties that
could cause the actual results to differ materially from the
expected results. Most of these factors are outside SeaStar
Medical’s control and are difficult to predict. Factors that may
cause actual future events to differ materially from the expected
results include, but are not limited to: (i) the inability to
recognize the anticipated benefits of the business combination with
LMAO, which may be affected by, among other things, competition and
the ability of the post-combination company to grow and manage
growth profitability and retain its key employees, (ii) future
capital requirements and sources and uses of cash, (iii) the
ability to obtain funding or raise capital for its operations and
future growth, (iv) the ability to maintain the listing of its
securities on Nasdaq, (v) any delays or challenges in obtaining FDA
approval Company’s SCD product candidates, (vi) the risk of
downturns and the possibility of rapid change in the highly
competitive industry in which SeaStar Medical operates, (vii) the
risk that SeaStar Medical and its current and future collaborators
are unable to successfully develop and commercialize its products
or services, or experience significant delays in doing so,
including failure to achieve approval of its products by applicable
federal and state regulators, (viii) the risk that SeaStar Medical
may never achieve or sustain profitability; (ix) the risk that
SeaStar Medical may need to raise additional capital to execute its
business plan, which may not be available on acceptable terms or at
all; (x) the risk that third-parties suppliers and manufacturers
are not able to fully and timely meet their obligations, (xi) the
risk of product liability or regulatory lawsuits or proceedings
relating to SeaStar Medical’s products and services, (xii) the risk
that SeaStar Medical is unable to secure or protect its
intellectual property, and (xiii) other risks and uncertainties
indicated in SeaStar Medical’s Annual Report on Form 10-K,
including those under “Risk Factors” section therein, and other
filings that have been made or will be made with the SEC. These
forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and SeaStar Medical assumes no obligation and does not
intend to update or revise these forward-looking statements,
whether as a result of new information, future events, or
otherwise.
Contact:
LHA Investor RelationsJody Cain(310)
691-7100Jcain@lhai.com
# # #
SeaStar Medical (NASDAQ:ICU)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
SeaStar Medical (NASDAQ:ICU)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024